The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

Learn about HMGB1's crucial role in liver diseases, its pathways and therapeutic potential that can treat liver diseases.

The liver is one of the body’s hardest-working organs, tirelessly filtering toxins, metabolising fats, and supporting ...

The risk increases significantly for individuals who carry these viruses long-term without treatment. While Hepatitis B has a ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Fourteen percent of the world's people -- more than 800 million -- now have diabetes, a doubling of the global rate for the ...

This treatment mediates long-term reversal of liver fibrosis ... Metabolic dysfunction-associated steatotic liver disease (MASLD), or "fatty liver disease," is the most common chronic liver disease ...

2 There are currently no treatments approved for MASLD, formerly known as nonalcoholic fatty liver disease. Instead, ...

While the treatment options for this aggressive type ... Cavefish Provide New Insight Into Fatty Liver Disease Mar. 18, 2024 — Fatty liver, which can lead to liver damage and disease, can ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with ...

Nonalcoholic fatty liver disease (NAFLD ... the pathogenesis of NAFLD and the current treatment and management of nonalcoholic steatohepatitis. Currently, maintaining a healthy weight through ...